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1. Introduction 
Neural stem cells (NSCs) are defined as clonogenic cells with self-renewal capacity and 
multilineage potential (Bazán et al., 2004). Cells with these characteristics have been isolated 
from the embryonic and adult Central Nervous System (CNS) (Gil-Perotin et al., 2009; 
Merkle & Alvarez-Buylla, 2006; Weiss et al., 1996). Under specific conditions, these cells 
proliferate in culture as cell clusters, called neurospheres, and differentiate into neurons, 
glia, and non-neural cell types (Kennea & Mehmet, 2002; Lobo et al., 2003; Reynolds & 
Weiss, 1992; Vescovi et al., 2002; Arias-Carrión & Yuan, 2009). Moreover, these cultures 
represent a potential source for cell replacement therapies in neurological diseases such as 
Parkinson’s disease (PD) (Bjugstad et al., 2008; Pluchino et al., 2005; Reimers et al., 2011; 
Zhu et al, 2009).  
Both basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) promote the 
proliferation of NSCs (Ciccolini & Svendsen, 1998; Gritti et al., 1996, 1999; Reynolds et al., 1992; 
Palmer et al., 1999). Moreover, growth factors (GFs) and intracellular mechanisms have been 
reported to influence or even determine NSCs phenotypic choice “in vivo” and “in vitro” 
(Daadi & Weiss, 1999; Hagg, 2005, 2009; Ninkovic & Götz, 2007; Redondo et al., 2007; 
Reimers et al., 2001, 2008). Thus, bFGF in combination with agents that increase cAMP levels 
and/or protein kinase C (PKC) activators induced the expression of tyrosine hydroxylase 
(TH), which is the rate-limiting enzyme involved in the synthesis of catecholaminergic 
neurotransmitters (Lopez-Toledano et al., 2004).  
Growth factors exert their action through their interaction with specific receptors. A subset 
of FGF receptors (FGFRs) have been described in NSCs and their progeny (Reimers et al., 
2001, Lobo et al., 2003), but to present nothing is known regarding the role played by these 
different FGFRs subtypes in the TH-inductive effect of bFGF above described. NSCs also 
express a 170 kD protein corresponding to the EGF receptor (EGFR) (Lobo et al., 2003). Since 
bFGF modulates EGF responsiveness in striatal precursors (Ciccolini & Svendsen, 1998), we 
wonderer whether TH induction in NSCs progeny could be associated with changes in 
EGFR protein expression and/or cellular localization.  
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2. Material and methods 
2.1 Isolation of neural stem cells from the embryonic rat striatum 
Striatal primordia from E15 Sprague-Dawley rat embryos were dissected and mechanically 
dissociated. Cells were grown in suspension in a defined medium (DF12) composed of 
Dulbecco's modified Eagle's medium and Ham's F-12 (1:1), 2 mM L-glutamine, 1 mM 
sodium piruvate (all from Gibco BRL, Life Technologies Inc, Grand Island, NY), 0.6% 
glucose, 25 g/ml insulin, 20 nM progesterone, 60 M putrescine, and 30 nM sodium 
selenite (all from Sigma Chemical Co, St Louis, MO), 100 g/ml human transferrin 
(Boehringer Mannheim GmbH, Germany) and 20 ng/ml human recombinant EGF 
(PreproTech EC Ltd., London, England). After 48-72 hr in vitro, the cells grew as free-
floating neurospheres and were passaged by mechanical dissociation every 2-3 days (Lobo 
et al., 2003; Reimers et al., 2001).  
After a minimum of 4 and a maximum of 5 passages, neurospheres were dissociated and 
plated at a density of 20,000–30,000 cells/cm2 on 15g/ml poly l-ornithine (Sigma)-coated 
round glass cover slips (ø12 mm) or plastic dishes (ø 35 mm). Cultures were maintained in 
DF12 and 20 ng/ml EGF for 3 days and then switched to DF12 without EGF for longer 
culture periods (control group). At 7 days postplating (dpp), parallel cultures were treated 
with 10 ng/ml human recombinant bFGF (Boehringer Mannheim) and 1 mM 
dibutyryladenosine 3,5-cyclic monophosphate (bFGF + dbcAMP) in the absence (vehicle 
group), or presence of 20M PD98058 or 10-7M staurosporin. Cellular phenotypes were 
determined immunocytochemically 24 hr later using antibodies to -tubulin isotype III (-
tubulin III) for neurons, glial fibrillary acidic protein (GFAP) for astrocytes, A2B5, which 
stains bipotential O2A glial progenitors (Raff et al. 1984; Schnitzer & Schachner 1982) as well 
as subsets of neurons (Schnitzer & Schachner 1982), O4 for immature oligodendrocytes, O1 
for mature oligodendrocytes, and TH for catecholaminergic phenotypes. 
2.2 Immunocytochemical staining 
The polyclonal antibodies used in this study were anti--tubulin III (BabCO; Richmond, CA), 
anti-TH (Chemicon International;Temecula, CA), anti-DOPA-decarboxilase (Sigma, Missouri, 
USA), anti-dopamine transporter (DAT, Chemicon), anti-vesicular monoamine transporter 2 
(VMAT2, Pel-Freez, Arkansas LLC, USA) and anti-GFAP (Dako; Glostrup, Denmark). The 
antibodies used for the detection of FGF receptors (FGFR1, FGFR2, FGFR3), and EGF receptor 
(EGFR) were from Santa Cruz Biotechnology Inc., Burlingame, CA, USA. Monoclonal 
antibodies against -tubulin III were obtained from Sigma, anti-TH was obtained from 
Chemicon, and anti-nestin (clone Rat 401) was from the Developmental Studies Hybridoma 
Bank (University of Iowa, Iowa City, IO). Monoclonal antibodies against A2B5, O4, and O1 
were obtained in our laboratory as hybridoma supernatants. The secondary antibodies used 
were: biotinylated goat anti-mouse IgG (Zymed Laboratories; South San Francisco, CA), 
streptavidin–biotin–peroxidase complex (DakoCytomation), diaminobenzidine (DAB) + 
substrate–chromogen system (both from DakoCytomation), Alexa Fluor-568 goat anti-mouse 
IgG, Alexa Fluor-488 donkey anti-rat IgG, and Alexa Fluor-488 goat anti-rabbit IgG (1:400; all 
from Molecular Probes; Eugene, OR), Fluorescein-conjugated goat anti-mouse IgG (1:25; 
Jackson ImmunoResearch Laboratories Inc, West Grove, PA), Cy3-conjugated donkey anti-
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guinea pig IgG (1:500, Jackson ImmunoResearch Laboratories Inc.), and Rhodamine-
conjugated goat anti-rabbit IgG (1:100, Chemicon International Inc.).  
For immunocytochemical studies, cells were fixed with 4% paraformaldehyde for 10 min 
and immunostained for A2B5 (1:10), O4 (1:10), O1 (1:10), FGFR1 (1:100), FGFR2 (1:100), 
FGFR3 (1:50) and EGFR (1:50) as previously described (Reimers et al., 2001). 
Permeabilization for GFAP (1:500), -tubulin III (1:200 for monoclonal and 1:3000 for 
polyclonal anti--tubulin III, and TH (1:500) was achieved by treating cultures with 0.05% 
Triton X-100 at 4°C for 5min. Immunofluorescent procedures were applied for neural 
antigens and FGFR3 detection, and immunoperoxidase methods for FGFR1 and FGFR2 
visualization. Cover slips were mounted in a medium containing p-phenylenediamine and 
bis-Benzimide (Hoechst 33342; Sigma). 
2.3 Western blot protein analysis 
NSCs progeny were treated for 24 hr with TH inducers, in the absence or presence of 20 M 
PD98058 or 10-7M staurosporin, and proteins were processed for Western blot analysis to 
determine the relative levels of growth factor receptors (GFRs) and neural antigens. Cells were 
lysed with 0.5 M Tris-HCl buffer (pH 7.4) containing 0.24% Triton X-100, 10 mg/ml leupeptin, 
and 0.5 mM PMSF, all from Sigma. After 1 hr at 4ºC, samples were centrifuged at 12,000g for 
30 min. Total protein content was quantified using a BCA kit (Pierce; Rockford, IL). Aliquots of 
30 g of protein were separated by electrophoresis on 10% SDS-polyacrylamide minigels and 
transferred to nitrocellulose filters. Membranes were soaked in blocking solution (0.2 M Tris-
HCl, 137 mM NaCl, and 3–5% dry skimmed milk, pH 7.6) and incubatedwith primary 
antibodies diluted in the same blocking solution: anti-FGFR1 (1:200), anti-FGFR3 (1:200), anti 
EGFR (1:250), anti-TH (1:10,000), and anti-GFAP (1:1000), anti--tubulin III (1:10,000), and anti-
CNPasa (1:1000). After extensive washing membranes were incubated with the peroxidase-
conjugated secondary antibodies diluted 1:1000 in blocking solution. The filters were 
developed with enhanced chemiluminescence Western blotting analysis, following the 
procedure described by the manufacturer (Amersham, Buckinghamshire, England). 
Membranes were immunolabeled for control charge using mouse anti- actine (1:5000; Sigma 
Aldrich). Autoradiograms were quantified by computer-assisted videodensitometry. 
2.4 Data analysis and cell counting 
For Western blot analysis, results are expressed as mean ± SEM from two to four 
independent experiments. Where indicated, data represent the mean ± SEM of several cover 
slips. For each cover slip, stereological sampling of 25 visual fields (magnification of 200x or 
400x) was performed by fluorescence microscopy. The number of cells was corrected for 
cover slip area. Statistical analyses were performed using Student’s t-test or one-way 
ANOVA followed by Newman-Keuls multiple comparison test, and differences were 
considered significant at p ≤ 0.05. 
3. Results and discussion 
3.1 Acquisition of a dopaminergic phenotype in the progeny of neural stem cells 
Previously, we demonstrated that bFGF in combination with the PKA activator dbcAMP 
induced TH immunoreactivity in a subset of neurons and A2B5-positive progenitors 
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derived from striatal EGF-expanded NSCs (striatal EGF-NSCs) (Lopez-Toledano et al., 
2004). However, to present nothing is known regarding the ability of bFGF + dbcAMP to 
promote the expression of other features of dopaminergic mature neurons in these cells. As 
shown in Fig. 1A, bFGF + dbcAMP treatment increased by 1.5-fold TH protein expression in 
the progeny derived from striatal EGF-NSCs. 
 
Fig. 1. Induction of a dopaminergic phenotype in the progeny derived from striatal EGF-NSCs. 
As shown in A-C, bFGF + dbcAMP treatment (black bars) increased the expression of TH 
(A), VMAT2 (B) and DAT (C). Note how 20 M PD98059 (vertical line bars) and 10-7M 
staurosporin (horizontal line bars) prevented TH protein overexpression (A). Line 1, control 
cultures, line 2, bFGF + dbcAMP treated cultures, line 3, bFGF + dbcAMP in the presence of 
PD98059, line 4, bFGF + dbcAMP in the presence of staurosporin. Results represent the 
mean ± SEM of 2 independent experiments. **p ≤ 0.01 vs control. D shows how in bFGF + 
dbcAMP treated cultures DOPA-decarboxilase immunoreactivity (D, green) associates with 
TH-positive cells (D, red, white arrows).   
In the presence of 20 M PD98059 or 10-7 M staurosporin, which are inhibitors of the 
mitogen activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK1/2) 
and PKC, respectively, the raise in TH protein levels promoted by bFGF + dbcAMP 
treatment was prevented (Fig. 1A). These results are in agreement with our previous studies 
showing that the activation of the MAPK/ERK1/2 signaling pathway and PKC activity 
were required for the generation of TH-positive cells in striatal EGF-NSCs progeny (Lopez-
Toledano et al., 2004). Besides TH, bFGF + dbcAMP treated cultures also showed DOPA-
decarboxilase immunoreactivity that in some cases was associated with TH-positive cells 
(Fig. 1D). This enzyme catalyzes the conversion of levodopa (L-DOPA) in dopamine, so we 
may consider that under TH-inductive conditions striatal EGF-NSCs progeny is able to 
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synthesize this neurotransmitter which deficit is involved in the progression of PD (Aron et 
al, 2011). As a matter of fact, our preliminary studies indicate that bFGF + dbcAMP 
treatment significantly increases L-DOPA levels by 1.7-fold (p ≤ 0.01 vs control). Moreover, 
in the presence of the DOPA-decarboxilase inhibitor NSD-1015, L-DOPA levels were 
significantly higher than those observed under control conditions (p ≤ 0.001), or bFGF + 
dbcAMP treatment (p ≤ 0.01). Altogether, these results strongly suggest that under our 
experimental conditions TH and DOPA-decarboxilase are active enzymes. 
We also analyzed the effect of the TH-inductive treatment in the expression of other 
dopaminergic markers such as VMAT2 and DAT. Thus, bFGF + dbcAMP increased by 2-
fold VMAT2 and DAT protein levels (Fig. 1B, C). The expression of both proteins was not 
regulated by the MAPK/ERK1/2 signaling pathway or PKC activity because neither 
PD98059, nor staurosporin prevented VMAT2 or DAT upregulation (Fig. 1C, D). In our 
cultures, bFGF + dbcAMP treatment increased the phosphorylation of the cyclic AMP 
response element binding protein (CREB) probably through the activation of PKA by 
dbcAMP (Lopez-Toledano et al., 2004). Because this transcription factor regulates the 
expression of catecholamine biosynthetic enzymes and transporters (Lewis-Tuffin et al., 
2004;  Lim et al., 2000; Watson et al., 2001), its activation could be responsible for the increase 
in VMAT2 and DAT protein levels observed in this study. Besides, bFGF + dbcAMP could 
stimulate striatal EGF-NSCs to release neurotrophins that are able to increase the expression 
of TH and monoamine transporters in neural precursors (Maciaczyk et al., 2008; Sun et al., 
2004), and in the damaged brain (Emborg et al., 2008).   
3.2 Dopaminergic inductors modulate the expression and cellular localization of 
fibroblast growth factor receptors in the progeny of neural stem cells 
Striatal EGF-NSCs and their progeny express a subset of FGFRs, so we were interested in to 
determine the role played by the different FGFR subtypes in the acquisition of dopaminergic 
features in these cells. FGFR1 is expressed in nestin-positive neural precursors (Lobo et al, 
2003), and was down-regulated during their differentiation in neurons and glial cells (Reimers 
et al., 2001). Under dopaminergic-inductive conditions, FGFR1 immunoreactivity was higher 
than in controls (Fig.2A, C). Similarly, FGFR1 protein expression was significantly raised by 
more than 10-fold in bFGF + dbcAMP treated cultures (Fig. 2B). FGFR1 up-regulation was not 
affected in the presence of MAPK/ERK1/2 or PKC inhibitors (Fig. 2B, D), indicating that other 
signaling pathways are involved in FGFR1 over-expression. Growth factors are able to 
stimulate the phosphatidylinositol 3-kinase (PI3K)/Akt signaling transduction pathway in 
NSCs to promote their proliferation, survival and differentiation (Lim et al., 2007; Meng et al, 
2011; Nguyen et al., 2009; Torroglosa et al., 2007). As mentioned above, FGFR1 is expressed in 
nestin-positive neural precursors. In our cultures, bFGF + dbcAMP treatment significantly 
increased nestin protein expression by 2-fold (p ≤ 0.05 vs control), and neither PD98059 nor 
staurosporin were able to abolish this effect. Because similar results were observed under 
bFGF treatment (Reimers et al., 2001), our results strongly suggest that the GF promotes the 
survival and/or proliferation of resting FGFR1-/nestin-positive neural precursors probably 
through the stimulation of PI3K/Akt signaling pathway.  
Dopaminergic-inductive conditions modulate FGFR3 protein expression and cellular 
localization. Under control conditions, FGFR3 was localized in the membrane of GFAP-
positive astrocytes (Fig. 3A), in the cell bodies of -tubulin III-positive neurons (Fig. 3B), and 
in the nuclei of O4-positive preoligodendrocytes (Fig. 3C). Western blot analysis revealed 
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that FGFR3 levels were significantly up-regulated by bFGF + dbcAMP treatment (Fig. 3D). 
This experimental condition changed the morphology of GFAP-positive cells that showed 
longer and thinner processes where FGFR3 immunoreactivity was observed (Fig. 3E). 
Moreover, FGFR3 immunostaining was also detected in their nuclei (Fig. 3E). bFGF + 
dbcAMP treatment also affected to the morphology of O4-positive cells and increased 
FGFR3 immunoreactivity in their nuclei (Fig. 3G). Besides, some TH-positive cells showing a 
neuronal morphology co-expressed FGFR3 in their cell bodies (Fig. 3F). Other authors have 
shown the presence of two forms of FGFR3 in the nucleus of malignant and non-malignant 
epithelial cells (Johnston et al., 1995; Zammit et al., 2001). However, to our knowledge this is 
the first study reporting the nuclear localization of FGFR3 in neural cells. From our results, it 
is difficult to determine whether the higher levels of FGFR3 nuclear staining observed in 
GFAP-positive cells are due to the increase in protein expression, or to the translocation of 
FGFR3 to perinuclear localization.  
 
Fig. 2. Tyrosine hydroxylase inductors upregulate FGFR1 protein expression in the progeny 
derived from striatal EGF-NSCs. A, C an D show FGFR1 immunocytochemical staining in 
control conditions (A), and in cultures treated with bFGF + dbcAMP (T) in the absence (C) 
or presence of 20 M PD98059 (D). Note how in the presence of TH-inductors FGFR1 
immunoreactivity is increased (C). bFGF + dbcAMP treatment also upregulates FGFR1 
protein expression (B, black bar), and this effect is not prevented by 20 M PD98059 (B, 
vertical lines bar) or 10-7M staurosporin (B, horizontal lines bar). Line 1, control cultures, line 
2, bFGF + dbcAMP treated cultures, line 3, bFGF + dbcAMP in the presence of PD98059, line 
4, bFGF + dbcAMP in the presence of staurosporin. Results represent the mean ± SEM of 2 
independent experiments. **p ≤ 0.01 vs control. 
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Fig. 3. Tyrosine hydroxylase inductors modulate FGFR3 protein expression and cellular 
localization in the progeny derived from striatal EGF-NSCs. A-C show how under control 
conditions FGFR3 immunoreactivity (green) is localized in the membranes of GFAP-positive 
astrocytes (A, white arrows), cell bodies of -tubulin III-positive neurons (B, yellow), and 
nuclei of O4-positive preoligodendrocytes (C). E-I show FGFR3 immunostaining in basic 
FGF + dbcAMP treated cultures (T). Under TH-inductive conditions, FGFR3 is localized in 
the nuclei of GFAP-positive astrocytes (E, white arrowheads) and preoligodendrocytes (G), 
and in the cell bodies of TH-positive neurons (F, yellow). Note, how astrocytes (E, red) and 
O4-positive cells (G, red) show longer and thinner extensions in bFGF + dbcAMP treated 
cultures, and how FGFR3 immunoreactivity is decreased in the presence of 20 M PD98059 
(H, green) and 10-7M staurosporin (I, green). TH inductors also upregulate FGFR3 protein 
expression (D, black bar), and this effect is prevented by 20 M PD98059 (D, vertical lines 
bar) or 10-7M staurosporin (D, horizontal lines bar). Line 1, control cultures, line 2, bFGF + 
dbcAMP treated cultures, line 3, bFGF + dbcAMP in the presence of PD98059, line 4, bFGF + 
dbcAMP in the presence of staurosporin. Results represent the mean ± SEM of 4 
independent experiments. *p ≤ 0.05 vs control, +p ≤ 0.05 vs vehicle. 
Interestingly, the nuclear translocation of FGFRs in response to bFGF has been reported in 
reactive astrocytes (Clarke et al., 2001) and Swiss 3T3 fibroblasts (Maher, 1996). Moreover, 
the antibody used in this study recognizes a 135 kDa form of FGFR3 that showed a mix of 
nuclear and cytoplasmic localization in epithelial cells that depends on its degree of 
activation by different members of the FGF family (Zammit et al., 2001).  
Similarly to TH protein expression, FGFR3 up-regulation was not observed in the presence 
of 20 M PD98059 or 10-7M staurosporin (Fig. 3D). FGFR3 immunoreactivity was also 
reduced in both experimental conditions (Fig. 3H, I). Moreover, PKC inhibition prevented 
the morphological changes promoted by bFGF + dbcAMP treatment (Fig. 3I). These results 
suggest that the modulation of FGFR3 and TH induction are two events closely associated. 
As a matter of fact, FGFRs nuclear localization has been related with the differentiation of 
neural progenitor cells (Fang et al., 2005; Stachowiak et al., 2003), and TH gene expression 
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(Peng et al., 2002). We should comment that not all TH-positive cells were FGFR3 
immunoreactive (our unpublished observations), so it seems that they are not direct targets 
for bFGF. Under our TH-inductive conditions, GFAP protein expression was significantly 
raised by more than 1.6-fold (p ≤ 0.05 vs control). GFAP over-expression and morphological 
changes are features of reactive glia which is able to synthesize trophic factors involved in 
neuronal survival and differentiation (Barreto et al., 2011). Because glial derived factors are 
also involved in the differentiation of NSCs in TH-immunoreactive dopaminergic neurons 
(Anwar et al., 2008; Maciaczyk et al., 2008; Sun et al., 2004), from our results we propose that 
stimulation of FGFR3 localized in glial cells mediate the release of several unknown factors 
that in combination with PKA activators stimulate TH-induction in the target cells. In fact, 
glial conditioned medium in combination with PKA activators elicits the expression of TH 
in the progeny of striatal EGF-NSCs (Reimers et al., 2008).  
We have also analyzed the effects of bFGF + dbcAMP treatment in FGFR2 expression. Under 
the experimental conditions presented in this study, FGFR2 nuclear localization and FGFR2 
protein expression were not affected (data not shown), indicating that probably this FGFR is 
not involved in the acquisition of a dopaminergic phenotype in striatal EGF-NSCs progeny. 
3.3 Tyrosine hydroxylase-inducing cues trigger nuclear epidermal growth factor 
receptor accumulation in the progeny of neural stem cells  
EGFR stimulation is essential for the proliferation of striatal EGF-NSCs (Bazán et al., 1998, 
2006; Reimers et al., 2001). EGFR protein expression has been detected during the 
differentiation of these cells in neurons and glia (Lobo et al., 2003); however, to present nothing 
is known regarding its cellular localization, and the role, if any, played by this receptor in the 
differentiation of striatal EGF-NSCs to TH-immunopositive cells. As shown in Fig. 4A, EGFR-
positive cells were observed in 8 dpp control cultures. At this experimental time, EGFR 
imuunoreactivity was localized in the cell bodies of -tubulin III- (Fig. 4B) and O4-positive 
cells (Fig. 4D). Moreover, EGFR immunostaining was also observed in the membrane of 
GFAP-positive astrocytes (Fig. 4C). TH-inductive conditions did not affect EGFR protein 
expression (Fig. 4K), but promoted the translocation of EGFR to the nuclei in many cells (Fig. 
4E). Nuclear EGFR immunoreactivity was observed in small spots, suggesting that the EGFR 
could be localized in the nucleolar compartment. Functional nuclear EGFR have been 
described in normal and tumoral cells (Jaganathan et al., 2011; Lo & Hung, 2007; Xu et al., 
2009), but to our knowledge this is the first study reporting the nuclear localization of EGFR in 
NSCs and its derived progeny. Interestingly, a recent report discusses the possibility that 
proliferation and differentiation of NSCs could be controlled by nuclear receptors (Katayama 
et al., 2005). Moreover, NSCs proliferation seems to be regulated by a nucleolar mechanism 
that involves the interaction of proteins located in their nucleoli (Tsai & McKay, 2002). Neither 
EGFR protein expression (Fig. 4K), nor nuclear localization (Fig. 4I) were affected in the 
presence of PD98059. However, both parameters were significantly reduced in the presence of 
the PKC inhibitor staurosporin (Fig. 4J, K). As a matter of fact, a recent report demonstrates 
that PKC activation triggers nuclear EGFR accumulation in a bronchial carcinoma cell line 
(Wanner et al., 2008). Besides, the nuclear translocalization of EGFR may require its 
phosphorylation at Ser-229 by Akt (Huang et al., 2011). Further experiments are warranted to 
determine whether the PI3K/Akt signaling pathway mediates bFGF + dbcAMP-induced 
EGFR nuclear translocalization in striatal EGF-NSCs.   
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Fig. 4. Tyrosine hydroxylase inductors elicit nuclear translocalization of EGFR in the 
progeny derived from striatal EGF-NSCs. In control cultures EGFR immunoreactivity is 
localized the cell bodies (A, red), and in membranes (A, white arrows). Under this condition, 
EGFR is expressed in the cell bodies of neurons (B, yellow) and O1-positive 
oligodendrocytes (D), and in the membranes of GFAP-positive astrocytes (C, open triangle). 
Note how bFGF + dbcAMP (T) translocates EGFR to the nuclear compartment (E, white 
arrowheads), and how nuclear EGFR is observed in a few -tubulin III-positive neurons (F, 
white star), a few astrocytes (G, open arrow), and in many A2B5-positive progenitors (H). 
Neither EGFR immunoreactivity nor nuclear EGFR localization are affected in the presence 
of 20 M PD98059 (I, red), but 10-7 M staurosporine significantly decreases both parameters 
(J, red). bFGF + dbcAMP treatment in the absence (K, black bar) or presence of 20 M 
PD98059 (K, vertical lines bar) does not affect EGFR protein expression; however, 10-7 M 
staurosporin significantly reduces EGFR levels (K, horizontal lines bar). Line 1, control 
cultures, line 2, bFGF + dbcAMP treated cultures, line 3, bFGF + dbcAMP in the presence of 
PD98059, line 4, bFGF + dbcAMP in the presence of staurosporin. Results represent the 
mean ± SEM of 2 independent experiments. +p ≤ 0.05 vs vehicle. 
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Double immunostaining showed that some neurons (Fig. 4F) and a few GFAP-positive 
astrocytes (Fig.4G) presented nuclear EGFR immunoreactivity. Besides, a population of cells 
showing EGFR nuclear localization colabeled with A2B5-positive cells (Fig.4H). Emerging 
evidence suggest that EGFR nuclear translocalization regulates gene expression and mediate 
other cellular processes such as DNA repair (Chen & Nirodi, 2007; Dittmann et al., 2010; Lo, 
2010). Its transcriptional activity depends on its C-terminal transactivation domain, and its 
physical and functional interaction with other transcription factors that lead the activation of 
genes (Lo & Hung, 2006). Under our experimental conditions TH is expressed in 4% of the 
total population of -tubulin III-positive neurons, and 20% of the TH-positive cells colabel 
with A2B5 (Lopez-Toledano et al., 2004), so we may hypothesize that nuclear EGFR could 
regulate TH gene expression in both cell types.  
 
Fig. 5. Schematic diagram illustrating how bFGF + dbcAMP treatment induces the 
expression of specific features of dopaminergic neurons in the progeny derived from striatal 
EGF-NSCs through the modulation of GFRs expression and cellular localization.  
4. Conclusions 
1. In striatal EGF-NSCs, bFGF + dbcAMP treatment up-regulates the expression of the 
specific dopaminergic markers TH, DAT and VMAT2.   
2. FGFR1 and nestin protein levels are significantly raised in bFGF + dbcAMP treated 
cultures, suggesting the survival and/or proliferation of undifferentiated neural 
precursors under this experimental condition. 
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3. bFGF + dbcAMP treatment increases FGFR3 protein expression and FGFR3 
immunoreactivity in the glial progeny derived from striatal-EGF-NSCs.  Moreover, this 
experimental condition up-regulates GFAP protein levels, and elicits the 
translocalization of FGFR3 to the nucleus in reactive GFAP-positive astrocytes.  
4. In the presence of MAPK/ERK1/2 or PKC inhibitors, TH protein expression, FGFR3 
up-regulation, and glial reactivity are partially prevented, suggesting that in bFGF + 
dbcAMP treated cultures, the modulation of FGFR3 in glial cells and TH induction are 
two events closely associated. 
5. Under bFGF + dbcAMP treatment, EGFR immunostaining shows a nuclear localization 
in -tubulin III-positive neurons and in A2B5-positive precursors derived from striatal 
EGF-NSCs. Because both cell types are able to express TH, we hypothesize that the 
nuclear translocalization of EGFR is necessary for the induction of TH in these cells. 
As summarize in Fig. 5, our results demonstrate that in striatal EGF-NSCs, bFGF and 
dbcAMP treatment induces TH protein expression through the stimulation of FGFR3 
expressed in glia, and nuclear translocalization of EGFR in the target cells. Under these TH-
inductive conditions, striatal EGF-NSCs progeny acquire other specific features of mature 
dopaminergic neurons, so they can be considered as an excellent tool for stem cell-based 
replacement therapies in PD.  
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